한글목차

• 2024년, GlobalData의 척수 손상 역학 예측에서 다루어지고 있는 16개국에서 18만 명을 넘는 척수 손상 환자가 예측됩니다.
• SCI 환자 치료에 대한 미충족 수요가 높으며, 현재 시장은 많은 제네릭 의약품과 증상 치료용 적응외 의약품으로 구성되어 있습니다.
• SCI의 파이프라인은 105개의 분자로 구성되어 있으며, 3종의 의약품이 3상 단계에 있고, 15종의 의약품이 2상 단계에 있습니다.
• 지난 10년간 SCI를 대상으로 시작된 임상시험의 약 41.45%는 북미에서 진행되었습니다.
• 북미와 남미에서는 라이선스 계약이 가장 일반적인 거래 유형입니다.

세계의 척수 손상(SCI) 시장에 대해 조사분석했으며, 질환 상황, 출시 약품과 파이프라인 약품 평가, 현재와 향후 경쟁 구도 등을 제공하고 있습니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약품 평가

• 주요 출시 약품
• 개요 : 작용기서별
• 개요 : 분자 유형별
• 제품의 개요와 판매 예측

제5장 가격결정과 상환 평가

• 연간 치료비
• 가격결정과 상환까지의 시간

제6장 파이프라인 약품 평가

• 중기부터 후기 파이프라인 약품
• 개요 : 개발 단계별
• 개요 : 작용기서별
• 개요 : 분자 유형별
• 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유 PTSR와 LoA

제7장 임상시험 평가

• 과거 개요
• 개요 : 단계별
• 개요 : 현황별
• 개요 : 단계별(진행중/계획 시험)
• 가상 컴포넌트에 의한 시험
• 시험 개요 : 지역별
• 단일국/다국간 시험 : 지역별
• 스폰서 상위 20사와 내역 : 단계별
• 스폰서 상위 20사와 내역 : 현황별
• 개요 : 엔드포인트 현황별
• 개요 : 인종/민족별
• 등록 데이터
• 시험 시설 상위 20개국
• 세계의 상위 20 시설
• 실현 가능성 분석 - 지역 목표 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴 : 지역별
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in spinal cord injury therapeutics.

• In 2024, more than 180,000 diagnosed incident cases of SCI are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for SCI.
• There is a high unmet need for treating patients with SCI, currently the market comprises many generics and off-label drugs for symptomatic treatment.
• The SCI pipeline comprises 105 molecules, with three drugs in Phase III and another 15 in Phase II.
• Approximately 41.45% of the clinical trials initiated over the last 10 years for SCI have been conducted in sites across North America.
• In North and South America, licensing agreements were the most common type of deal.

Scope

GlobalData's spinal cord injury: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the spinal cord injury market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global spinal cord injury market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer